Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of vebicortotamab in previously treated advanced biliary tract cancer
ChiCTR2600133501Phase 2Not yet recruiting
- Sponsor
- Jiangmen Central Hospital
- Start
- Aug 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vebicortotamab in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer, sponsored by Jiangmen Central Hospital. Primary endpoint: Objective response rate. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
vebicortotamab
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on ChiCTR2600133501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133501.